Avelumab
BAVENCIO (avelumab) is a prescription monoclonal antibody used in immunotherapy to treat certain cancers by blocking PD-L1, helping the immune system fight tumor cells. It's given as an intravenous infusion at a strength of 20 mg/mL. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | BAVENCIO (avelumab) is a prescription monoclonal antibody used in immunotherapy to treat certain cancers by blocking PD-L1, helping the immune system fight tumor cells. It's given as an intravenous infusion at a strength of 20 mg/mL. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Avelumab",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Avelumab — ANDA 761049 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761049"
}
]
|
| identifier | ANDA761049 |
| issued | 2016-09-16 |
| keyword |
[
"drug-safety",
"fda",
"health-care",
"pharmaceuticals",
"prescription-drugs"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Avelumab |
